This week we wave goodbye to the United Kingdom and all its glory and through the English channel, we head south to charming Switzerland. Geneva is our destination and it is where Addex Therapeutics, our Biotech of the Week, is based.
City: Geneva (Switzerland)
Market Capitalization: €30M (3/2016)
CEO: Tim Dyer
Mission: Founded in 2002, Addex Therapeutics, a biopharmaceutical company, focuses on the development of novel, orally available, small molecule allosteric modulators for neurological disorders. The company integrated drug development capabilities (e.g in vitro, preclinical and clinical development experts) with relevant experience within the pharmaceutical industry as their key move.
By taking advice from world-renowned researchers and scientists, Addex Therapeutics’ team was able to create and develop significant knowledge on allosteric modulation and were able to improve orally allosteric drugs for unmet medical needs, making them pioneers and main developers on this field.